News

PDS Biotechnology Corp (PDSB) – Conference Call Clarifies Data and Mechanism of PDS0101

Health
0 min read

Wednesday, June 08, 2022

PDS Biotechnology Corp (PDSB)
Conference Call Clarifies Data and Mechanism of PDS0101

PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer and infectious disease immunotherapies based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technology platforms. Our Versamune®-based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. The Company’s pipeline products address various cancers including HPV16-associated cancers (anal, cervical, head and neck, penile, vaginal, vulvar) and breast, colon, lung, prostate and ovarian cancers.

Robert LeBoyer, Vice President, Research Analyst, Life Sciences , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

PDS Held A Conference Call Following ASCO Data Presentations.  On June 7, PDS management held a conference call to discuss the full data from its presentations at the American Society for Clinical Oncology (ASCO) meeting on June 5 and 6.  The presentations were from the Phase 2 VERSATILE-002 trial testing PDS0101 in head and neck cancer and the Phase 2 Triple Combination trial testing PDS0101 with two immune modulating drugs in multiple tumor types.

Two Trials Presented Data At ASCO.  PDS0101 was developed using the PDS Versamune technology to stimulate an immune response to HPV16, an immune marker found on human papilloma virus (HPV) related cancers.  The VERSATILE-002 trial tested PDS0101 the combination with Merck’s pembrolizumab (Keytruda), using the checkpoint inhibitor to make the tumor recognizable to the immune system along with PDS0101 to improve the immune response and kill the tumor cells….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Share

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2024 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.